Catharina Johanna Alberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catharina Johanna Alberts has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Damien Georges
International Agency for Research on Cancer (IARC/WHO), Early Detection Prevention and Infections Branch, Lyon, France
3 shared publicationsMaarten F. Schim van der Loeff
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, The Netherlands
3 shared publicationsAndrea Gini
International Agency for Research on Cancer (IARC/WHO), Early Detection Prevention and Infections Branch, Lyon, France
2 shared publications- Ariadna Feliu
Department of Primary Care and Public Health, Imperial College London, London, UK
2 shared publications - Carolina Espina
Environmental and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
2 shared publications Catherine de Martel
Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
2 shared publications
Latest Publications
- Open Access
Modelling the expected and potentially preventable burden of infection-related cancer among newly arrived migrants in the European Union
International migration is rising globally. Newly arrived migrants (defined as individuals relocating into countries in the European Union) are a European Centre for Disease Prevention and Control (ECDC) priority population for entry health assessments—offering opportunities to prevent infection-related cancers but rarely implemented in practice. Using migration, cancer incidence, and intervention data, we modelled the burden of hepatocellular carcinoma (HCC), cervical cancer (CvC), and gastric cancer (GC) and the proportion potentially preventable by interventions: HBV vaccination, HBV and HCV screen-and-treat, HPV vaccination, cervical screening, and H. pylori screen-and-treat. We estimated 635,000 cancer cases over their lifetime (144,000 HCC, 155,000 CvC, 336,000 GC). Assuming full uptake, ECDC-recommended hepatitis interventions could prevent 15% of HCC cases; HPV vaccination and cervical screening could prevent 65% and 60% of CvC cases among eligible migrants, respectively; and H. pylori screen-and-treat could prevent 44% of GC cases among all migrants. Expanding eligibility could further increase impact.
Open AccessModelling the expected and potentially preventable burden of infection-related cancer among newly arrived migrants in the European Union
International migration is rising globally. Newly arrived migrants (defined as individuals relocating into countries in the European Union) are a European Centre for Disease Prevention and Control (ECDC) priority population for entry health assessments—offering opportunities to prevent infection-related cancers but rarely implemented in practice. Using migration, cancer incidence, and intervention data, we modelled the burden of hepatocellular carcinoma (HCC), cervical cancer (CvC), and gastric cancer (GC) and the proportion potentially preventable by interventions: HBV vaccination, HBV and HCV screen-and-treat, HPV vaccination, cervical screening, and H. pylori screen-and-treat. We estimated 635,000 cancer cases over their lifetime (144,000 HCC, 155,000 CvC, 336,000 GC). Assuming full uptake, ECDC-recommended hepatitis interventions could prevent 15% of HCC cases; HPV vaccination and cervical screening could prevent 65% and 60% of CvC cases among eligible migrants, respectively; and H. pylori screen-and-treat could prevent 44% of GC cases among all migrants. Expanding eligibility could further increase impact.
- Open Access
Cancer incidence in first-generation migrants and host populations in seven European registries, including Ukrainian-born migrants in Poland: a population-based study
SUMMARY: Background: Where people are born shapes their cancer risk, yet European cancer surveillance rarely records migration background. We estimated cancer incidence in first-generation migrants and assessed whether birth-country incidence stratifies their cancer risk. Methods: We harmonised data from six population-based cancer registries in Belgium, the Netherlands, Spain (Murcia, Tarragona), Italy (Turin), and Switzerland (Ticino) for 2003–17, examining breast, colorectal, cervical, stomach, liver, and lung cancer in first-generation migrants and host populations. Countries-of-birth were grouped into quartiles of GLOBOCAN age-standardised incidence by cancer site and sex ( birth-country incidence categories ). We estimated cumulative risks (CR) and migrant-to-host cumulative risk ratios (CRR). Ukrainian-born migrants in Poland were analysed separately for 2022–23. Findings: Migrants’ cancer risk increased with birth-country incidence for cervical, stomach, and liver cancer. For cervical cancer, CRR rose from close to 1 in migrants from low-incidence countries to 4·9 (95% CI 3·5–6·9) in those from high-incidence countries in Turin. Breast and colorectal cancer diagnosis risk was lower than in host populations in every category. Across the six cancers combined, migrants had lower risk in 9 of 11 registry–sex strata, as lower breast, colorectal, and lung cancer risk outweighed higher cervical, stomach, and liver cancer risk. Ukrainian-born migrants in Poland (n=4450) had higher CR at most anatomical sites than the host population. Interpretation: Migrants’ cancer risk relative to host populations depends on country of birth and cancer site. Birth-country incidence is a useful way of grouping migrants by risk. National averages can mask residual risk in subgroups, e.g. migrants born in high-incidence countries had up to five times the cervical cancer risk of host populations with rates near or below the WHO elimination threshold. Routine recording of country of birth can support risk-tailored prevention and cancer service planning for displaced populations. Funding: ZonMw-09150162210124; IARC-WHO; and participating cancer registries. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed, Embase, and Web of Science from inception to Oct 15, 2026, without language restrictions, for population-based studies reporting cancer incidence among first-generation migrants in Europe compared with host populations. We used terms for migration (eg, “migrant”, “immigrant”, “country of birth”), cancer, and incidence. Existing studies specific on migrants in Europe remain sparse and fragmented, with most studies limited to individual countries, migrant groups, or cancer types. They differed in how migrants were grouped, in their reference populations, and in their methods, and often had small numbers per country of birth. A 2010 review reported higher incidence of infection-related cancers among migrants grouped as “non-western”, and similar or lower incidence of breast and colorectal cancer, but heterogeneity prevented quantitative analyses. These differences have been attributed mainly to factors acquired before migration, notably infections, possibly compounded by differences in access to healthcare and preventive services, including lower participation in screening. Comparable estimates across European populations have been lacking. So has evidence on whether birth-country incidence can stratify migrants by cancer risk, and on what registries can capture after recent large-scale displacement. Added value of this study: To our knowledge, this is the first harmonised multi-country analysis to group first-generation migrants by cancer incidence in their country of birth, using data from population-based cancer registries. For cervical, stomach, and liver cancer, cumulative risk among migrants followed the incidence ranking of their countries of birth. For breast and colorectal cancer, it was consistently lower than in host populations, independent of the country of birth. In most settings, the combined burden of the six cancers was lower among migrants. Grouping countries of birth by publicly available national incidence estimates gives a first population-level picture of the cancer profile of migrant populations. A case study of Ukrainian-born migrants in Poland shows what registry data can and cannot analyse and describe after large-scale displacement. Implications of all the available evidence: Routine recording of country of birth in cancer registries can generate evidence for equitable cancer control, supporting planning of prevention, screening and care services for settled and newly arrived migrants, particularly for infection-related cancers. The harmonised protocol and openly available analytic tools developed for this study can be applied by other registries for further research and routine surveillance. Harmonising migration-related data collection across European registries would strengthen surveillance and cancer service planning for displaced populations, and support equity-oriented cancer control policies.
Open AccessCancer incidence in first-generation migrants and host populations in seven European registries, including Ukrainian-born migrants in Poland: a population-based study
SUMMARY: Background: Where people are born shapes their cancer risk, yet European cancer surveillance rarely records migration background. We estimated cancer incidence in first-generation migrants and assessed whether birth-country incidence stratifies their cancer risk. Methods: We harmonised data from six population-based cancer registries in Belgium, the Netherlands, Spain (Murcia, Tarragona), Italy (Turin), and Switzerland (Ticino) for 2003–17, examining breast, colorectal, cervical, stomach, liver, and lung cancer in first-generation migrants and host populations. Countries-of-birth were grouped into quartiles of GLOBOCAN age-standardised incidence by cancer site and sex ( birth-country incidence categories ). We estimated cumulative risks (CR) and migrant-to-host cumulative risk ratios (CRR). Ukrainian-born migrants in Poland were analysed separately for 2022–23. Findings: Migrants’ cancer risk increased with birth-country incidence for cervical, stomach, and liver cancer. For cervical cancer, CRR rose from close to 1 in migrants from low-incidence countries to 4·9 (95% CI 3·5–6·9) in those from high-incidence countries in Turin. Breast and colorectal cancer diagnosis risk was lower than in host populations in every category. Across the six cancers combined, migrants had lower risk in 9 of 11 registry–sex strata, as lower breast, colorectal, and lung cancer risk outweighed higher cervical, stomach, and liver cancer risk. Ukrainian-born migrants in Poland (n=4450) had higher CR at most anatomical sites than the host population. Interpretation: Migrants’ cancer risk relative to host populations depends on country of birth and cancer site. Birth-country incidence is a useful way of grouping migrants by risk. National averages can mask residual risk in subgroups, e.g. migrants born in high-incidence countries had up to five times the cervical cancer risk of host populations with rates near or below the WHO elimination threshold. Routine recording of country of birth can support risk-tailored prevention and cancer service planning for displaced populations. Funding: ZonMw-09150162210124; IARC-WHO; and participating cancer registries. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed, Embase, and Web of Science from inception to Oct 15, 2026, without language restrictions, for population-based studies reporting cancer incidence among first-generation migrants in Europe compared with host populations. We used terms for migration (eg, “migrant”, “immigrant”, “country of birth”), cancer, and incidence. Existing studies specific on migrants in Europe remain sparse and fragmented, with most studies limited to individual countries, migrant groups, or cancer types. They differed in how migrants were grouped, in their reference populations, and in their methods, and often had small numbers per country of birth. A 2010 review reported higher incidence of infection-related cancers among migrants grouped as “non-western”, and similar or lower incidence of breast and colorectal cancer, but heterogeneity prevented quantitative analyses. These differences have been attributed mainly to factors acquired before migration, notably infections, possibly compounded by differences in access to healthcare and preventive services, including lower participation in screening. Comparable estimates across European populations have been lacking. So has evidence on whether birth-country incidence can stratify migrants by cancer risk, and on what registries can capture after recent large-scale displacement. Added value of this study: To our knowledge, this is the first harmonised multi-country analysis to group first-generation migrants by cancer incidence in their country of birth, using data from population-based cancer registries. For cervical, stomach, and liver cancer, cumulative risk among migrants followed the incidence ranking of their countries of birth. For breast and colorectal cancer, it was consistently lower than in host populations, independent of the country of birth. In most settings, the combined burden of the six cancers was lower among migrants. Grouping countries of birth by publicly available national incidence estimates gives a first population-level picture of the cancer profile of migrant populations. A case study of Ukrainian-born migrants in Poland shows what registry data can and cannot analyse and describe after large-scale displacement. Implications of all the available evidence: Routine recording of country of birth in cancer registries can generate evidence for equitable cancer control, supporting planning of prevention, screening and care services for settled and newly arrived migrants, particularly for infection-related cancers. The harmonised protocol and openly available analytic tools developed for this study can be applied by other registries for further research and routine surveillance. Harmonising migration-related data collection across European registries would strengthen surveillance and cancer service planning for displaced populations, and support equity-oriented cancer control policies.
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63, 101592
European Code Against Cancer 5th edition: 14 ways you can help prevent cancer
- 23 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63, 101592
Top Cited PapersOpen AccessEuropean Code Against Cancer 5th edition: 14 ways you can help prevent cancer
- Top Cited PapersOpen Access
- 16 January 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (1) , 96-116
European Code Against Cancer, 5th edition – cancer‐causing infections and related interventions
The main infections that cause cancer in the European Union (EU) are Helicobacter pylori ( H. pylori ), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Altogether, in 2022, these infections accounted for ~ 5% of all cancers in the EU, mainly of the stomach, cervix uteri and liver. The largest burden of infection‐caused cancers was found in the south of the EU and near the eastern border. Substantial progress in the efficacy of interventions against these infections has been made since the release of the 4th edition of the European Code Against Cancer in 2015. Cancers due to infections can increasingly be prevented by prophylactic vaccines (HPV and HBV) and/or prompt diagnosis and treatment that can either cure (HCV and H. pylori ) or slow down the infection (HBV and HIV), thus substantially reducing disease risk. Tools to tackle carcinogenic infections are also increasingly accessible and affordable in the EU, but their implementation is slow. Public awareness, political will and cost‐effective protocols are necessary to establish large programmes of vaccination or testing and treatment. Progress monitoring, as well as avoiding disinformation and stigma, is crucial to ensure that advances in medical progress are fully leveraged. The recently published 5th edition of the European Code Against Cancer therefore recommends: (1) vaccinate girls and boys against HBV and HPV at the age recommended in your country; (2) take part in testing and treatment for HBV and HCV, HIV and H. pylori , as recommended in your country.
- 16 January 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (1) , 96-116
Top Cited PapersOpen AccessEuropean Code Against Cancer, 5th edition – cancer‐causing infections and related interventions
The main infections that cause cancer in the European Union (EU) are Helicobacter pylori ( H. pylori ), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Altogether, in 2022, these infections accounted for ~ 5% of all cancers in the EU, mainly of the stomach, cervix uteri and liver. The largest burden of infection‐caused cancers was found in the south of the EU and near the eastern border. Substantial progress in the efficacy of interventions against these infections has been made since the release of the 4th edition of the European Code Against Cancer in 2015. Cancers due to infections can increasingly be prevented by prophylactic vaccines (HPV and HBV) and/or prompt diagnosis and treatment that can either cure (HCV and H. pylori ) or slow down the infection (HBV and HIV), thus substantially reducing disease risk. Tools to tackle carcinogenic infections are also increasingly accessible and affordable in the EU, but their implementation is slow. Public awareness, political will and cost‐effective protocols are necessary to establish large programmes of vaccination or testing and treatment. Progress monitoring, as well as avoiding disinformation and stigma, is crucial to ensure that advances in medical progress are fully leveraged. The recently published 5th edition of the European Code Against Cancer therefore recommends: (1) vaccinate girls and boys against HBV and HPV at the age recommended in your country; (2) take part in testing and treatment for HBV and HCV, HIV and H. pylori , as recommended in your country.
- Top Cited PapersOpen Access
- 14 May 2022
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 7 (8) , 724-735
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review
- 14 May 2022
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 7 (8) , 724-735
Top Cited PapersOpen AccessWorldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review
- Open Access
- 1 April 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (4) , e0010199
Larval source reduction with a purpose: Designing and evaluating a household- and school-based intervention in coastal Kenya
Background: Since Aedes aegypti mosquitoes preferentially breed in domestic containers, control efforts focus on larval source reduction. Our objectives were to design and test the effectiveness of a source reduction intervention to improve caregiver knowledge and behaviors in coastal Kenya. Methodology/Principal findings: We conducted a cluster-randomized controlled trial with 261 households from 5 control villages and 259 households from 5 intervention villages. From each household, one child (10–16 years old) and his or her primary caregiver participated in the intervention. We assessed caregiver knowledge and behavior at baseline, as well as 3 and 12 months after the intervention. We assessed household entomological indices at baseline and 12 months after the intervention to avoid seasonal interference. We conducted qualitative interviews with 34 caregivers to understand barriers and facilitators to change. We counted and weighed containers collected by children and parents during a community container clean-up and recycling event. After 12 months, caregiver knowledge about and self-reported behavior related to at least one source reduction technique was more than 50 percentage points higher in the intervention compared to control arm (adjusted risk differences for knowledge: 0.69, 95% CI [0.56 to 0.82], and behavior: 0.58 [0.43 to 0.73]). Respondents stated that other family members’ actions were the primary barriers to proper container management. The number of containers at households did not differ significantly across arms even though children and parents collected 17,200 containers (1 ton of plastics) which were used to planted 4,000 native trees as part of the community event. Conclusions/Significance: Our study demonstrates that source reduction interventions can be effective if designed with an understanding of the social and entomological context. Further, source reduction is not an individual issue, but rather a social/communal issue, requiring the participation of other household and community members to be sustained.
- 1 April 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (4) , e0010199
Open AccessLarval source reduction with a purpose: Designing and evaluating a household- and school-based intervention in coastal Kenya
Background: Since Aedes aegypti mosquitoes preferentially breed in domestic containers, control efforts focus on larval source reduction. Our objectives were to design and test the effectiveness of a source reduction intervention to improve caregiver knowledge and behaviors in coastal Kenya. Methodology/Principal findings: We conducted a cluster-randomized controlled trial with 261 households from 5 control villages and 259 households from 5 intervention villages. From each household, one child (10–16 years old) and his or her primary caregiver participated in the intervention. We assessed caregiver knowledge and behavior at baseline, as well as 3 and 12 months after the intervention. We assessed household entomological indices at baseline and 12 months after the intervention to avoid seasonal interference. We conducted qualitative interviews with 34 caregivers to understand barriers and facilitators to change. We counted and weighed containers collected by children and parents during a community container clean-up and recycling event. After 12 months, caregiver knowledge about and self-reported behavior related to at least one source reduction technique was more than 50 percentage points higher in the intervention compared to control arm (adjusted risk differences for knowledge: 0.69, 95% CI [0.56 to 0.82], and behavior: 0.58 [0.43 to 0.73]). Respondents stated that other family members’ actions were the primary barriers to proper container management. The number of containers at households did not differ significantly across arms even though children and parents collected 17,200 containers (1 ton of plastics) which were used to planted 4,000 native trees as part of the community event. Conclusions/Significance: Our study demonstrates that source reduction interventions can be effective if designed with an understanding of the social and entomological context. Further, source reduction is not an individual issue, but rather a social/communal issue, requiring the participation of other household and community members to be sustained.
- 23 September 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (4) , 990-999
Human papillomavirus vaccination uptake: a longitudinal study showing ethnic differences in the influence of the intention-to-vaccinate among parent-daughter dyads
It is unclear what role daughters play in the decision-making process regarding HPV vaccination. Therefore, we explored the impact of HPV vaccination intention among parents and their 12–13 year-ol...
- 23 September 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (4) , 990-999
Human papillomavirus vaccination uptake: a longitudinal study showing ethnic differences in the influence of the intention-to-vaccinate among parent-daughter dyads
It is unclear what role daughters play in the decision-making process regarding HPV vaccination. Therefore, we explored the impact of HPV vaccination intention among parents and their 12–13 year-ol...
- 8 April 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (12) , 2164-2166
Molecular Risk Stratification for Anal Cancer Prevention
Gary M Clifford, Catharina J Alberts; Molecular risk-stratification for anal cancer prevention, Clinical Infectious Diseases, , ciaa399, https://doi.org/10.109
- 8 April 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (12) , 2164-2166
Molecular Risk Stratification for Anal Cancer Prevention
Gary M Clifford, Catharina J Alberts; Molecular risk-stratification for anal cancer prevention, Clinical Infectious Diseases, , ciaa399, https://doi.org/10.109
- Open Access
- 9 March 2020
- Published by Wiley in Helicobacter
- Vol. 25 (3) , e12687
Helicobacter pylori seroprevalence in six different ethnic groups living in Amsterdam: The HELIUS study
Background: Helicobacter pylori prevalence varies greatly worldwide. We explored the prevalence of H. pylori and CagA seropositivity among adults aged 18‐44 years living in the Netherlands by ethnicity and migration status (first vs second generation).Materials and Methods: Participants from six different ethnic groups were selected from the population‐based multi‐ethnic HELIUS study in Amsterdam, the Netherlands. Serum samples were tested for H. pylori antigens using a validated Luminex‐based multiplex serology assay. Prevalence ratios were estimated using Poisson regression analysis.Results: A total of 4683 participants aged 18‐44 years were randomly selected based on sex, ethnicity, and age. H. pylori seroprevalence was highest in the Ghanaian group (84%), followed by Moroccan (81%), Turkish (66%), African Surinamese (51%), South‐Asian Surinamese (48%), and Dutch (17%) participants. All ethnic minority groups had a significantly higher risk of being H. pylori seropositive compared to the Dutch group. This association was strongest among participants born outside the Netherlands (first generation), but was still significant and apparent among second‐generation participants. Among first‐generation participants, all groups, except the Moroccans, had a significantly higher proportion of individuals with a cagA + H. pylori strain compared to the Dutch participants.Conclusion: Helicobacter pylori seroprevalence among first‐generation migrants is high in the Netherlands and remains elevated among second‐generation migrants (ie, those born in the Netherlands). High exposure to H. pylori, and especially to the more virulent cagA+ strain, highlights the need for tailored prevention of gastric diseases (notably peptic ulcers and cancers) among migrants.
- 9 March 2020
- Published by Wiley in Helicobacter
- Vol. 25 (3) , e12687
Open AccessHelicobacter pylori seroprevalence in six different ethnic groups living in Amsterdam: The HELIUS study
Background: Helicobacter pylori prevalence varies greatly worldwide. We explored the prevalence of H. pylori and CagA seropositivity among adults aged 18‐44 years living in the Netherlands by ethnicity and migration status (first vs second generation).Materials and Methods: Participants from six different ethnic groups were selected from the population‐based multi‐ethnic HELIUS study in Amsterdam, the Netherlands. Serum samples were tested for H. pylori antigens using a validated Luminex‐based multiplex serology assay. Prevalence ratios were estimated using Poisson regression analysis.Results: A total of 4683 participants aged 18‐44 years were randomly selected based on sex, ethnicity, and age. H. pylori seroprevalence was highest in the Ghanaian group (84%), followed by Moroccan (81%), Turkish (66%), African Surinamese (51%), South‐Asian Surinamese (48%), and Dutch (17%) participants. All ethnic minority groups had a significantly higher risk of being H. pylori seropositive compared to the Dutch group. This association was strongest among participants born outside the Netherlands (first generation), but was still significant and apparent among second‐generation participants. Among first‐generation participants, all groups, except the Moroccans, had a significantly higher proportion of individuals with a cagA + H. pylori strain compared to the Dutch participants.Conclusion: Helicobacter pylori seroprevalence among first‐generation migrants is high in the Netherlands and remains elevated among second‐generation migrants (ie, those born in the Netherlands). High exposure to H. pylori, and especially to the more virulent cagA+ strain, highlights the need for tailored prevention of gastric diseases (notably peptic ulcers and cancers) among migrants.
- Open Access
- 3 December 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 612
Differences in Chlamydia trachomatis seroprevalence between ethnic groups cannot be fully explained by socioeconomic status, sexual healthcare seeking behavior or sexual risk behavior: a cross-sectional analysis in the HEalthy LIfe in an Urban Setting (HELIUS) study
In the Netherlands, there are strong disparities in Chlamydia trachomatis (CT) prevalence between ethnic groups. The current study aims to identify whether socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior may explain differences in CT seroprevalence between ethnic groups. We used 2011–2014 baseline data of the HELIUS (HEalthy LIfe in an Urban Setting) study, a multi-ethnic population-based cohort study in Amsterdam, the Netherlands, including participants from Dutch, African Surinamese, South-Asian Surinamese, Ghanaian, Moroccan and Turkish origin. For this analysis, we selected sexually active, heterosexual participants aged 18–34 years old. CT seroprevalence was determined using a multiplex serology assay. The CT seroprevalence ratios between different ethnicities are calculated and adjusted for potential indicators of socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior. The study population consisted of 2001 individuals (52.8% female) with a median age of 28 years (IQR 24–31). CT seropositivity differed by ethnicities and ranged from 71.6% (African Surinamese), and 67.9% (Ghanaian) to 31.1% (Turkish). The CT seroprevalence ratio of African Surinamese was 1.72 (95% CI 1.43–2.06) and 1.52 (95% CI 1.16–1.99) of Ghanaian as compared to the Dutch reference group, after adjustment for socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior. Indicators of socioeconomic status, sexual risk behavior, and sexual health seeking behavior could not explain the higher CT seroprevalence among African Surinamese and Ghanaian residents of Amsterdam.
- 3 December 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 612
Open AccessDifferences in Chlamydia trachomatis seroprevalence between ethnic groups cannot be fully explained by socioeconomic status, sexual healthcare seeking behavior or sexual risk behavior: a cross-sectional analysis in the HEalthy LIfe in an Urban Setting (HELIUS) study
In the Netherlands, there are strong disparities in Chlamydia trachomatis (CT) prevalence between ethnic groups. The current study aims to identify whether socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior may explain differences in CT seroprevalence between ethnic groups. We used 2011–2014 baseline data of the HELIUS (HEalthy LIfe in an Urban Setting) study, a multi-ethnic population-based cohort study in Amsterdam, the Netherlands, including participants from Dutch, African Surinamese, South-Asian Surinamese, Ghanaian, Moroccan and Turkish origin. For this analysis, we selected sexually active, heterosexual participants aged 18–34 years old. CT seroprevalence was determined using a multiplex serology assay. The CT seroprevalence ratios between different ethnicities are calculated and adjusted for potential indicators of socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior. The study population consisted of 2001 individuals (52.8% female) with a median age of 28 years (IQR 24–31). CT seropositivity differed by ethnicities and ranged from 71.6% (African Surinamese), and 67.9% (Ghanaian) to 31.1% (Turkish). The CT seroprevalence ratio of African Surinamese was 1.72 (95% CI 1.43–2.06) and 1.52 (95% CI 1.16–1.99) of Ghanaian as compared to the Dutch reference group, after adjustment for socioeconomic status, sexual risk behavior and sexual healthcare seeking behavior. Indicators of socioeconomic status, sexual risk behavior, and sexual health seeking behavior could not explain the higher CT seroprevalence among African Surinamese and Ghanaian residents of Amsterdam.